Liquidia Technologies (LQDA)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Pulmonarysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 14/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 19.89% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Liquidia (LQDA) Could Be 74% Undervalued As Court Ruling Clouds YUTREPIA Access
- Stocktwits Wall Street Wrap: Analysts Turn Bullish On Sweetgreen, Target And Airbnb – Liquidia And FICO Face Downgrades
- United Therapeutics Just Sent Liquidia Stock Lower After Patent Battle
- Stocks making big moves yesterday: United Therapeutics, Moderna, Jabil, Concentrix, and FactSet
- LQDA Stock On Track For Worst Week Ever As Analysts Say The Yutrepia Patent Loss Clouds Its Path
- Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback
- United Therapeutics Won Its Patent War and Liquidia Collapsed
- Liquidia Sinks Another 17% as BofA Cuts Target to $40 From $92 After Court Loss
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Liquidia Technologies.
Full LQDA Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.